Economic impact of Juvenile Idiopathic Arthritis: a systematic review
Abstract Background Juvenile Idiopathic Arthritis (JIA) requires complex care that generate elevated costs, which results in a high economic impact for the family. The aim of this systematic review was to collect and cluster the information currently available on healthcare costs associated with JIA...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-10-01
|
| Series: | Pediatric Rheumatology Online Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12969-021-00641-y |
| _version_ | 1818916415149703168 |
|---|---|
| author | Fernando García-Rodríguez Augusto Gamboa-Alonso Sol Jiménez-Hernández Lucero Ochoa-Alderete Valeria Alejandra Barrientos-Martínez Neri Alejandro Alvarez-Villalobos Gabriela Andrea Luna-Ruíz Ingris Peláez-Ballestas Ana Victoria Villarreal-Treviño Manuel Enrique de la O-Cavazos Nadina Rubio-Pérez |
| author_facet | Fernando García-Rodríguez Augusto Gamboa-Alonso Sol Jiménez-Hernández Lucero Ochoa-Alderete Valeria Alejandra Barrientos-Martínez Neri Alejandro Alvarez-Villalobos Gabriela Andrea Luna-Ruíz Ingris Peláez-Ballestas Ana Victoria Villarreal-Treviño Manuel Enrique de la O-Cavazos Nadina Rubio-Pérez |
| author_sort | Fernando García-Rodríguez |
| collection | DOAJ |
| description | Abstract Background Juvenile Idiopathic Arthritis (JIA) requires complex care that generate elevated costs, which results in a high economic impact for the family. The aim of this systematic review was to collect and cluster the information currently available on healthcare costs associated with JIA after the introduction of biological therapies. Methods We comprehensively searched in MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Databases for studies from January 2000 to March 2021. Reviewers working independently and in duplicate appraised the quality and included primary studies that report total, direct and/or indirect costs related to JIA for at least one year. The costs were converted to United States dollars and an inflationary adjustment was made. Results We found 18 eligible studies including data from 6,540 patients. Total costs were reported in 10 articles, ranging from $310 USD to $44,832 USD annually. Direct costs were reported in 16 articles ($193 USD to $32,446 USD), showing a proportion of 55 to 98 % of total costs. Those costs were mostly related to medications and medical appointments. Six studies reported indirect costs ($117 USD to $12,385 USD). Four studies reported costs according to JIA category observing the highest in polyarticular JIA. Total and direct costs increased up to three times after biological therapy initiation. A high risk of reporting bias and inconsistency of the methodology used were found. Conclusion The costs of JIA are substantial, and the highest are derived from medication and medical appointments. Indirect costs of JIA are underrepresented in costs analysis. |
| first_indexed | 2024-12-20T00:17:48Z |
| format | Article |
| id | doaj.art-4d4ab61d0d234ceebbfcc7d262b94ff6 |
| institution | Directory Open Access Journal |
| issn | 1546-0096 |
| language | English |
| last_indexed | 2024-12-20T00:17:48Z |
| publishDate | 2021-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Pediatric Rheumatology Online Journal |
| spelling | doaj.art-4d4ab61d0d234ceebbfcc7d262b94ff62022-12-21T20:00:17ZengBMCPediatric Rheumatology Online Journal1546-00962021-10-0119111010.1186/s12969-021-00641-yEconomic impact of Juvenile Idiopathic Arthritis: a systematic reviewFernando García-Rodríguez0Augusto Gamboa-Alonso1Sol Jiménez-Hernández2Lucero Ochoa-Alderete3Valeria Alejandra Barrientos-Martínez4Neri Alejandro Alvarez-Villalobos5Gabriela Andrea Luna-Ruíz6Ingris Peláez-Ballestas7Ana Victoria Villarreal-Treviño8Manuel Enrique de la O-Cavazos9Nadina Rubio-Pérez10Department of Pediatrics, Hospital Universitario “Dr. José E. González”, Universidad Autónoma de Nuevo LeónPlataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit México), Universidad Autonoma de Nuevo LeonDepartment of Pediatrics, Hospital Universitario “Dr. José E. González”, Universidad Autónoma de Nuevo LeónDepartment of Pediatrics, Hospital Universitario “Dr. José E. González”, Universidad Autónoma de Nuevo LeónDepartment of Pediatrics, Hospital Universitario “Dr. José E. González”, Universidad Autónoma de Nuevo LeónPlataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit México), Universidad Autonoma de Nuevo LeonDepartamento de Economía, Universidad IberoamericanaRheumatology Unit, Hospital General de México “Dr. Eduardo Liceaga”Department of Pediatrics, Hospital Universitario “Dr. José E. González”, Universidad Autónoma de Nuevo LeónDepartment of Pediatrics, Hospital Universitario “Dr. José E. González”, Universidad Autónoma de Nuevo LeónDepartment of Pediatrics, Hospital Universitario “Dr. José E. González”, Universidad Autónoma de Nuevo LeónAbstract Background Juvenile Idiopathic Arthritis (JIA) requires complex care that generate elevated costs, which results in a high economic impact for the family. The aim of this systematic review was to collect and cluster the information currently available on healthcare costs associated with JIA after the introduction of biological therapies. Methods We comprehensively searched in MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Databases for studies from January 2000 to March 2021. Reviewers working independently and in duplicate appraised the quality and included primary studies that report total, direct and/or indirect costs related to JIA for at least one year. The costs were converted to United States dollars and an inflationary adjustment was made. Results We found 18 eligible studies including data from 6,540 patients. Total costs were reported in 10 articles, ranging from $310 USD to $44,832 USD annually. Direct costs were reported in 16 articles ($193 USD to $32,446 USD), showing a proportion of 55 to 98 % of total costs. Those costs were mostly related to medications and medical appointments. Six studies reported indirect costs ($117 USD to $12,385 USD). Four studies reported costs according to JIA category observing the highest in polyarticular JIA. Total and direct costs increased up to three times after biological therapy initiation. A high risk of reporting bias and inconsistency of the methodology used were found. Conclusion The costs of JIA are substantial, and the highest are derived from medication and medical appointments. Indirect costs of JIA are underrepresented in costs analysis.https://doi.org/10.1186/s12969-021-00641-yJuvenile Idiopathic ArthritisEconomic impactDirect costsBurdenSystematic review |
| spellingShingle | Fernando García-Rodríguez Augusto Gamboa-Alonso Sol Jiménez-Hernández Lucero Ochoa-Alderete Valeria Alejandra Barrientos-Martínez Neri Alejandro Alvarez-Villalobos Gabriela Andrea Luna-Ruíz Ingris Peláez-Ballestas Ana Victoria Villarreal-Treviño Manuel Enrique de la O-Cavazos Nadina Rubio-Pérez Economic impact of Juvenile Idiopathic Arthritis: a systematic review Pediatric Rheumatology Online Journal Juvenile Idiopathic Arthritis Economic impact Direct costs Burden Systematic review |
| title | Economic impact of Juvenile Idiopathic Arthritis: a systematic review |
| title_full | Economic impact of Juvenile Idiopathic Arthritis: a systematic review |
| title_fullStr | Economic impact of Juvenile Idiopathic Arthritis: a systematic review |
| title_full_unstemmed | Economic impact of Juvenile Idiopathic Arthritis: a systematic review |
| title_short | Economic impact of Juvenile Idiopathic Arthritis: a systematic review |
| title_sort | economic impact of juvenile idiopathic arthritis a systematic review |
| topic | Juvenile Idiopathic Arthritis Economic impact Direct costs Burden Systematic review |
| url | https://doi.org/10.1186/s12969-021-00641-y |
| work_keys_str_mv | AT fernandogarciarodriguez economicimpactofjuvenileidiopathicarthritisasystematicreview AT augustogamboaalonso economicimpactofjuvenileidiopathicarthritisasystematicreview AT soljimenezhernandez economicimpactofjuvenileidiopathicarthritisasystematicreview AT luceroochoaalderete economicimpactofjuvenileidiopathicarthritisasystematicreview AT valeriaalejandrabarrientosmartinez economicimpactofjuvenileidiopathicarthritisasystematicreview AT nerialejandroalvarezvillalobos economicimpactofjuvenileidiopathicarthritisasystematicreview AT gabrielaandrealunaruiz economicimpactofjuvenileidiopathicarthritisasystematicreview AT ingrispelaezballestas economicimpactofjuvenileidiopathicarthritisasystematicreview AT anavictoriavillarrealtrevino economicimpactofjuvenileidiopathicarthritisasystematicreview AT manuelenriquedelaocavazos economicimpactofjuvenileidiopathicarthritisasystematicreview AT nadinarubioperez economicimpactofjuvenileidiopathicarthritisasystematicreview |